Spotlight
We have deep ties to the scientific and pharma industries and are supporting key breakthroughs and life-changing treatments for patients. Biopharma accounts for more than 50% of our revenue. Our portfolio of nearly 6 million different products is used in virtually every stage of the most important research, development and production work, such as monoclonal antibodies, cell and gene therapy, vaccines.
Our products are specified in more than 80% of the top 20 biologic drugs and we serve each of the world’s top 10 medical device companies.
Our strength in biopharma is underscored by the crucial role we are playing in the fight against the COVID-19 pandemic.